Dopamine Transporter Neuroimaging as an Enrichment Biomarker in Early Parkinson's Disease Clinical Trials: A Disease Progression Modeling Analysis

Clinical and Translational Science

Volumn 11, Issue 1, 2018, Pages 63-70

  Conrado, Daniela J ^a   Nicholas, Timothy ^b   Tsai, Kuenhi ^c   Macha, Sreeraj ^c   Sinha, Vikram ^c   Stone, Julie ^c   Corrigan, Brian ^b   Bani, Massimo ^d   Muglia, Pierandrea ^a   Watson, Ian A ^e   Kern, Volker D ^a   Sheveleva, Elena ^a,f   Marek, Kenneth ^g   Stephenson, Diane T ^a   Romero, Klaus ^a  

^a CRITICAL PATH INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

^d UCB Inc   (Belgium)

^e ELI LILLY AND COMPANY   (United States)

^f UNIVERSITY OF ARIZONA   (United States)

^g INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MARKER; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROIMAGING; OBSERVATIONAL STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; SCORING SYSTEM; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; STAGING; BIOLOGICAL MODEL; BRAIN; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; EVALUATION STUDY; METABOLISM; MIDDLE AGED; MOLECULAR IMAGING; MONTE CARLO METHOD; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PATIENT DROPOUT; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; BRAIN; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; MOLECULAR IMAGING; MONTE CARLO METHOD; MOTOR ACTIVITY; NEUROIMAGING; PARKINSON DISEASE; PATIENT DROPOUTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 85026304892     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12492     Document Type: Article

References (20)

1. Kalia, L.V. & Lang, A.E. Parkinson's disease. Lancet 386, 896–912 (2015).
2. Ascherio, A. & Schwarzschild, M.A. The epidemiology of Parkinson's disease: risk factors and prevention. Lancet Neurol. 15, 1257–1272 (2016).
3. American Academy of Neurology. Compelling Statistics. [Internet]. https://www.aan.com/uploadedFiles/Website_Library_Assets/Documents/6.Public_Policy/1.Stay_Informed/4.Public_Policy_Resources/compell.pdf. Accessed 19 January 2017.
4. Connolly, B.S. & Lang, A.E. Pharmacological treatment of Parkinson disease: a review. JAMA 311, 1670–1683 (2014).
5. Marek, K. et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT study. Neurology 82, 1791–1797 (2014).
6. Booth, T.C., Nathan, M., Waldman, A.D., Quigley, A.M., Schapira, A.H. & Buscombe, J. The role of functional dopamine-transporter SPECT imaging in parkinsonian syndromes, part 1. AJNR Am. J. Neuroradiol. 36, 229–235 (2015).
7. General Electric Company. DaTscan (Ioflupane I 123 Injection) for intravenous use. Full prescribing information. [Internet]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022454Orig1s000Lbl.pdf (2011). Accessed 30 January 2017.
8. GE Healthcare Limited. DaTSCAN 74 MBq/ml solution for injection. Summary of product characteristics. [Internet]. https://www.ema.europa.eu/docs/en_GB/document_library/EPAR_/_Product_Information/human/000266/WC500035355.pdf (2010). Accessed 30 January 2017.
9. Stephenson, D. et al. Precompetitive data sharing as a catalyst to address unmet needs in Parkinson's disease. J. Parkinsons Dis. 5, 581–594 (2015).
10. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 69, 1480–1490 (2007).
11. Parkinson Progression Marker Initiative et al. The Parkinson Progression Marker Initiative (PPMI). Prog. Neurobiol. 95, 629–635 (2011).
12. Goetz, C.G., Stebbins, G.T. & Tilley, B.C. Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores. Mov. Disord. 27, 1239–1242 (2012).
13. Conrado, D.J., Chen, D. & Denney, W.S. Cardiovascular safety assessment in early-phase clinical studies: a meta-analytical comparison of exposure-response models. CPT Pharmacometrics Syst. Pharmacol. 5, 324–335 (2016).
14. Shulman, L.M., Gruber-Baldini, A.L., Anderson, K.E., Fishman, P.S., Reich, S.G. & Weiner, W.J. The clinically important difference on the unified Parkinson's disease rating scale. Arch. Neurol. 67, 64–70 (2010).
15. Cohen, J. A power primer. Psychol. Bull. 112, 155–159 (1992).
16. Marshall, V.L. et al. Parkinson's disease is overdiagnosed clinically at baseline in diagnostically uncertain cases: a 3-year European multicenter study with repeat [123I]FP-CIT SPECT. Mov. Disord. 24, 500–508 (2009).
17. Hill, D.L. et al. Coalition against major diseases/European Medicines Agency biomarker qualification of hippocampal volume for enrichment of clinical trials in predementia stages of Alzheimer's disease. Alzheimers Dement. 10, 421–429 (2014).
18. Venuto, C.S., Potter, N.B., Ray Dorsey, E. & Kieburtz, K. A review of disease progression models of Parkinson's disease and applications in clinical trials. Mov. Disord. 31, 947–956 (2016).
19. Smithson, M. & Verkuilen, J. A better lemon squeezer? Maximum-likelihood regression with beta-distributed dependent variables. Psychol. Methods 11, 54–71 (2006).
20. Conrado, D.J., Denney, W.S., Chen, D. & Ito, K. An updated Alzheimer's disease progression model: incorporating non-linearity, beta regression, and a third-level random effect in NONMEM. J. Pharmacokinet. Pharmacodyn. 41, 581–598 (2014).